News · 26 weeks140-6%
2025-12-282026-06-21
Mix6890d
- Other28(41%)
- Insider27(40%)
- SEC Filings8(12%)
- Dividends3(4%)
- Earnings1(1%)
- Analyst1(1%)
Latest news
25 items- PRPfizer Announces Topline Phase 3 Results for Sigvotatug Vedotin in Previously Treated Metastatic Non-Squamous Non-Small Cell Lung CancerPfizer Inc. (NYSE:PFE) today announced topline results from the Phase 3 SigVie-002 study (previously known as Be6A Lung-01) evaluating sigvotatug vedotin, an investigational, potential first-in-class integrin beta-6 (IB6) directed antibody-drug conjugate (ADC). The study enrolled adults with locally advanced, unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) who had received one or more lines of prior therapy. In the overall population, sigvotatug vedotin did not show a statistically significant improvement in the primary endpoint of overall survival (OS) compared to docetaxel. The safety profile of sigvotatug vedotin was manageable and consistent with prior s
- SECPfizer Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - PFIZER INC (0000078003) (Filer)
- SECPfizer Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - PFIZER INC (0000078003) (Filer)
- PRPfizer Announces Chief Financial Officer TransitionPfizer Inc. (NYSE:PFE) today announced that Dave Denton, Chief Financial Officer, will step down from his current role and leave the company on August 15 for a professional opportunity outside of the pharmaceutical industry in consumer goods, which he has accepted. The company has named Cecile Guegan, currently Senior Vice President, Finance, Global Biopharmaceutical Business, as Interim Chief Financial Officer, effective August 16, while Pfizer conducts a comprehensive internal and external search. Dave and Cecile will work together to ensure a seamless transition. "Dave has been a steady and trusted steward of Pfizer's financial health, and we are grateful for his leadership, especially
- INSIDERSEC Form 4 filed by Chairman & CEO Bourla Albert4 - PFIZER INC (0000078003) (Issuer)
- SECSEC Form 11-K filed by Pfizer Inc.11-K - PFIZER INC (0000078003) (Filer)
- SECSEC Form 11-K filed by Pfizer Inc.11-K - PFIZER INC (0000078003) (Filer)
- INSIDERSVP & Controller Damico Jennifer B. sold $51,400 worth of shares (2,000 units at $25.70), decreasing direct ownership by 6% to 31,397 units (SEC Form 4)4 - PFIZER INC (0000078003) (Issuer)
- ANALYSTPfizer upgraded by RBC Capital Mkts with a new price targetRBC Capital Mkts upgraded Pfizer from Underperform to Sector Perform and set a new price target of $25.00
- PRCancer's Toughest Targets Are Drawing Wall Street's Attention as Oncology Innovation AcceleratesDENVER, June 09, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com) – Artificial intelligence continues to dominate healthcare headlines, but another transformative story is quietly unfolding across biotechnology: the race to develop more effective treatments for some of the deadliest forms of cancer. From precision oncology and targeted therapies to next-generation approaches designed to overcome treatment resistance, a new wave of innovation is emerging that could reshape cancer care over the next decade. One area drawing increasing attention is neuro-oncology, particularly therapies targeting glioblastoma multiforme (GBM) and other aggressive brain cancers. Despite decades of research an
- FDAFDA Approval for HYMPAVZI issued to PFIZER INCSubmission status for PFIZER INC's drug HYMPAVZI (SUPPL-3) with active ingredient MARSTACIMAB-HNCQ has changed to 'Approval' on 06/05/2026. Application Category: BLA, Application Number: 761369, Application Classification:
- PRU.S. FDA Approves Pfizer's HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical NeedApproval expands HYMPAVZI use to now include people with hemophilia A or B ages 12 years and older with inhibitors and pediatric patients (ages 6 to 11 years) with or without inhibitors HYMPAVZI is the first subcutaneous non-factor therapy available for pediatric patients with hemophilia B ages 6 to 11 years old Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for HYMPAVZI® (marstacimab-hncq) to include the treatment of patients with hemophilia A or B 12 years and older with inhibitors and pediatric patients (ages 6 to 11 years) with or without inhibitors. HYMPAVZI is now indicated in the U.S. for routine prop
- PRRobust Phase 2b Efficacy and Favorable Tolerability Support Monthly Dosing for Pfizer's GLP-1 RA BerobenatideResults from multiple Phase 2b dose finding studies for berobenatide (PF'3944) highlight a potential first-in-class monthly GLP-1 receptor agonist (GLP-1 RA) peptide, and support the planned Phase 3 low, medium and high dosing strategy VESPER-1 achieved a non-placebo-adjusted weight loss of almost 16% with no plateau observed at 32 weeks on 2.4 mg weekly berobenatide Pfizer plans to advance 10 Phase 3 studies for berobenatide in 2026 for chronic weight management and obesity-related comorbidities including knee osteoarthritis and obstructive sleep apnea, as part of a broader program of 20+ obesity trials Pfizer Inc. (NYSE:PFE) today presented detailed results from multiple Phase 2
- INSIDERSEC Form 4 filed by Chairman & CEO Bourla Albert4 - PFIZER INC (0000078003) (Issuer)
- PRPfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare ConferencePfizer Inc. (NYSE:PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the Goldman Sachs 47th Annual Global Healthcare Conference on Monday, June 8, 2026 at 8:00 a.m. EDT. To listen to the webcast, visit our web site at www.pfizer.com/investors. Information on accessing and registering for the webcast will be available at www.pfizer.com/investors beginning today. The transcript and webcast replay of the discussion will be made available on our web site at www.pfizer.com/investors within 24 hours after the end of the live discussion and will be accessible for at least 90 days. About Pfizer: Bre
- PRLilly's Cancer Bombshell Sparks Hunt for the Next Oncology Stock Set to ExplodeDENVER, June 01, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com) – Eli Lilly (NYSE:LLY) has once again captured the attention of the oncology community after reporting remarkably strong Phase 3 results for Retevmo (selpercatinib) in early-stage RET fusion-positive non-small cell lung cancer. The LIBRETTO-432 study demonstrated an 83% reduction in the risk of disease recurrence or death versus placebo, potentially establishing Retevmo as a new standard of care in the adjuvant setting. The data were selected for presentation during the prestigious Plenary Session at the 2026 ASCO Annual Meeting and will be simultaneously published in The New England Journal of Medicine. For investors, the
- PRPfizer's BRAFTOVI Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal CancerCohort 3 analysis from the Phase 3 BREAKWATER study showed a 56% reduction in the risk of disease progression or death compared to traditional chemotherapy regimen Overall survival benefit was also observed, with a 44% reduction in the risk of death BRAFTOVI in combination with cetuximab and fluorouracil-based chemotherapy is the only approved targeted regimen for BRAF V600E-mutant metastatic colorectal cancer Pfizer Inc. (NYSE:PFE) today announced detailed progression-free and overall survival results from Cohort 3, a randomized cohort of the Phase 3 BREAKWATER trial, evaluating BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and FOLFIRI (fluorouracil
- PRTALZENNA Plus XTANDI Improves Radiographic Progression-Free Survival by More Than 50% in Metastatic Prostate CancerFirst PARP inhibitor + ARPI combination to show consistent rPFS improvement in HRR gene‑altered metastatic hormone‑sensitive prostate cancer, including both BRCA and non‑BRCA alterations There was an estimated 77% probability of remaining progression-free at three years with TALZENNA plus XTANDI Detailed results from pivotal TALAPRO-3 study presented at ASCO 2026 and published in The New England Journal of Medicine Pfizer Inc. (NYSE:PFE) today announced detailed results from the pivotal Phase 3 TALAPRO-3 study of TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI® (enzalutamide), an androgen receptor pathway inhibitor (ARPI),
- PRSeven-Year Analysis from Pfizer's LORBRENA CROWN Trial Shows Longest Progression-Free Survival Reported to Date in Advanced Non-Small Cell Lung CancerPatients had a 55% likelihood of remaining alive without disease progression at seven years, and median progression-free survival was not reached with LORBRENA Updated follow-up analysis solidifies LORBRENA as a preferred standard of care, building upon five-year results Pfizer Inc. (NYSE:PFE) today announced unprecedented seven-year follow-up results from the Phase 3 CROWN trial evaluating LORBRENA® (lorlatinib, a third-generation ALK inhibitor, available in Europe under the brand name LORVIQUA®) versus XALKORI® (crizotinib) in people with previously untreated, anaplastic lymphoma kinase (ALK)-positive advanced or metastatic non-small cell lung cancer (NSCLC). At seven years, pati
- PRInnovent Biologics and Pfizer Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology MedicinesSAN FRANCISCO and NEW YORK, and SUZHOU, China, May 28, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (01801.HK) and Pfizer Inc. (NYSE:PFE), today announced the companies have entered into a strategic global licensing and collaboration agreement for the research and development of 12 promising new breakthrough early-stage and de novo cancer medicines. The partnership includes licensing, co-development, and co-commercialization opportunities across a diverse portfolio of antibody-drug conjugates (ADCs) with novel differentiated payloads and multi-specific antibodies with differentiated immune-engaging features and unique designs. The strategic collaboration brings together Innovent's scientifi
- PRPfizer and Innovent Biologics Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology MedicinesPfizer Inc. (NYSE:PFE) and Innovent Biologics, Inc. (01801.HK), today announced the companies have entered into a strategic global licensing and collaboration agreement for the research and development of 12 promising new breakthrough early-stage and de novo cancer medicines. The partnership includes licensing, co-development, and co-commercialization opportunities across a diverse portfolio of antibody-drug conjugates (ADCs) with novel differentiated payloads and multi-specific antibodies with differentiated immune-engaging features and unique designs. The strategic collaboration brings together Pfizer's deep scientific expertise, global clinical development capabilities, regulatory lead
- PRPfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare ConferencePfizer Inc. (NYSE:PFE) invites investors and the general public to view and listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the Jefferies Global Healthcare Conference in New York on Wednesday, June 3, 2026 at 2:00 p.m. EDT. To view and listen to the webcast, visit our web site at www.pfizer.com/investors. Information on accessing and registering for the webcast will be available at www.pfizer.com/investors beginning today. The transcript and webcast replay of the discussion will be made available on our web site at www.pfizer.com/investors within 24 hours after the end of the live discussion and will be accessible for at least 90 days.
- PRPfizer Advances Pivotal Pediatric Pneumococcal Vaccine Program Following Strong Positive Phase 2 ResultsPhase 2 data demonstrate robust immunogenicity, including enhanced response against serotype 3, alongside expanded protection across 25 serotypes; to achieve potential vaccine serotype coverage of 90% in the pediatric population An oral presentation at ISPPD highlighted an approximately 9 to 15-fold higher serotype 3 immunogenicity response after Dose 3 and 4 in infants receiving Pfizer's 25-valent vaccine candidate (25vPnC) compared to PREVNAR 20® The investigational vaccine candidate was well-tolerated with no safety concerns identified in a Phase 2 study Based on these encouraging results from the Phase 2 program across serotypes and discussions with regulatory authorities, Pfi
- INSIDERSEC Form 4 filed by Chairman & CEO Bourla Albert4 - PFIZER INC (0000078003) (Issuer)
- PRAstellas to Present Data on Long-Term Outcomes and Clinical Use of Its Portfolio Across Disease Stages at ASCO 202610 abstracts, including two oral presentations, reinforce Astellas' long-term commitment to advancing oncology careTOKYO, May 18, 2026 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced it will present new data across its oncology portfolio at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 29 - June 2 in Chicago, reinforcing Astellas' sustained commitment to improving outcomes for people living with cancer. The data will provide further insight into the durable efficacy of established treatment approaches, their use in clinical practice, and ongoing areas of research and development.
PFE FAQ
6 questionsWhat does Pfizer Inc. do?
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zithromax, Vfend, and Panzyga brands. The company also provides medicines and...Where does PFE stock trade?
Pfizer Inc. (PFE) is listed on NYSE.What sector and industry is PFE in?
Pfizer Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about PFE?
Pfizer Inc. has had 8 recent analyst actions on file. The most recent action was from RBC Capital Mkts: Sector Perform with a $2500.00 price target on 2026-06-10. Recent price targets range from $2500.00 to $3500.00.What companies are similar to PFE?
Notable peers in the same industry include JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), MRK (Merck & Company Inc.), NVS (Novartis AG), GSK (GSK plc). Compare PFE side-by-side with any of them on Quantisnow.How can I track PFE on Quantisnow?
Quantisnow aggregates Pfizer Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PFE to receive live email and push alerts on every new disclosure.